Novo Nordisk A/S (NVO) vs Pfizer Inc. (PFE)
NVO leads on 10 of 15 compared metrics.
A side-by-side comparison of Novo Nordisk A/S and Pfizer Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 17, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
Total return — NVO vs PFE
growth of $100 · last 30yNVO +6242.2%PFE +119.7%NVO compounded faster
Log scale — wide-divergence pair
NVO PFE
NVO vs PFE: by the numbers
- •NVO is the larger company ($193.39B vs $148.41B market cap).
- •NVO trades at the lower earnings multiple (10.18 vs 19.88 P/E).
- •NVO converts more revenue to profit (37.14% vs 11.83% net margin).
- •NVO grew revenue faster over the past five years (20.73% vs 8.22% CAGR).
- •PFE pays the higher dividend yield (6.61% vs 4.14%).
Which is better, NVO or PFE?
Metric tally: NVO 10 · PFE 5It depends on what you're optimizing for:
ValueNVO(lower P/E)
GrowthNVO(faster 5Y revenue CAGR)
IncomePFE(higher dividend yield)
QualityNVO(higher ROIC)
Metrics side by side
Valuation
| Metric | NVO | PFE |
|---|---|---|
| P/E ratio | 10.18● | 19.88 |
| Forward P/E | — | 9.22 |
| P/S ratio | 3.78 | 2.36● |
| P/B ratio | 6.18 | 1.66● |
| PEG ratio | 8.17 | — |
| EV / EBITDA | 7.34● | 12.66 |
| FCF yield | 2.50% | 6.35%● |
Profitability
| Metric | NVO | PFE |
|---|---|---|
| Gross margin | 81.83%● | 69.35% |
| Operating margin | 45.21%● | 23.45% |
| Net margin | 37.14%● | 11.83% |
| ROE | 60.74%● | 8.31% |
| ROIC | 29.53%● | 8.84% |
Dividends
| Metric | NVO | PFE |
|---|---|---|
| Dividend yield | 4.14% | 6.61%● |
| Payout ratio | 49.80% | 126.47% |
Growth (annualized)
| Metric | NVO | PFE |
|---|---|---|
| Revenue CAGR (5Y) | 20.73%● | 8.22% |
| EPS CAGR (5Y) | 19.59%● | -3.78% |
| FCF CAGR (5Y) | -5.86% | -3.79%● |
| Total return CAGR (5Y) | 3.15%● | -3.04% |
Frequently asked
- Which is better, NVO or PFE?
- It depends on your goal. value: NVO (lower P/E); growth: NVO (faster 5Y revenue CAGR); income: PFE (higher dividend yield); quality: NVO (higher ROIC). Across all compared metrics, NVO leads 10 to 5.
- Is NVO or PFE cheaper?
- On trailing earnings, NVO is cheaper: NVO trades at a 10.18 P/E and PFE at 19.88.
- Which has grown faster, NVO or PFE?
- Over the past five years, NVO grew revenue faster — NVO at a 20.73% CAGR versus PFE at 8.22%.
- Does NVO or PFE pay a bigger dividend?
- NVO yields 4.14% and PFE yields 6.61% based on trailing dividends and the latest price.
- Is NVO or PFE more profitable?
- NVO runs the higher net margin — NVO at 37.14% versus PFE at 11.83%.
- Which has been the better investment, NVO or PFE?
- Over the past 10-year, NVO delivered the higher annualized total return — NVO at 7.88% versus PFE at 2.22%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Novo Nordisk A/S P/E ratioPfizer P/E ratioNovo Nordisk A/S dividend yieldPfizer dividend yieldNovo Nordisk A/S ROEPfizer ROENovo Nordisk A/S operating marginPfizer operating marginNovo Nordisk A/S revenue growthPfizer revenue growthNovo Nordisk A/S free cash flowPfizer free cash flow
Novo Nordisk A/S & Pfizer appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 17, 2026.